SCHEMBL6799649

SCHEMBL6799649

NC(=O)c1ccc(N2CCC(Cc3ccccc3)CC2)c(NC(=O)Nc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 11/20 0.55
TNKS O95271 1/20 0.53
PARP1 P09874 1/20 0.53
PARP14 Q460N5 1/20 0.53
FAAH O00519 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
POLB P06746 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
GRIN1 Q05586 1/20 0.47
GRIN2A Q12879 1/20 0.47
GRIN2B Q13224 1/20 0.47
GRIN2C Q14957 1/20 0.47
GRIN3A Q8TCU5 1/20 0.47
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29968547 1.00 CCR3 (0.55) CCR3TNKSPARP1PARP14FAAH
SCHEMBL6798325 0.91 GAA (0.53) CCR3TNKSPARP1PARP14FAAH
SCHEMBL29968508 0.85 PARP14 (0.50) TNKSPARP1PARP14GAAMAPT
SCHEMBL6797486 0.85 PARP14 (0.50) TNKSPARP1PARP14GAAMAPT
SCHEMBL6684996 0.84 KDM4E (0.53) FAAHGAAMAPTKDM4ELMNA
SCHEMBL29967752 0.84 KDM4E (0.53) FAAHGAAMAPTKDM4ELMNA
SCHEMBL6803523 0.82 MAPT (0.49) GAAMAPTKDM4ELMNATP53
SCHEMBL29968697 0.82 MAPT (0.49) GAAMAPTKDM4ELMNATP53
SCHEMBL6792633 0.79 LMNA (0.51) GAAMAPTKDM4ELMNATP53
SCHEMBL29968476 0.79 LMNA (0.51) GAAMAPTKDM4ELMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040242639-A1 Phospholipase C inhibitors for use in treating inflammatory disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2004-12-02 US claimed
WO-2004089901-A2 PHOSPHOLIPASE C INHIBITORS FOR USE IN TREATING INFLAMMATORY DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2004-10-21 WO claimed
US-20250017878-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY CHRONIC AIRWAY THERAPEUTICS LTD (AU) 2025-01-16 US disclosed
CN-117999073-A Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway 慢性呼吸道治疗有限公司 2024-05-07 CN disclosed
EP-4304717-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY Chronic Airway Therapeutics Limited (AU) 2024-01-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250017878-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY ARRB1, ADRB2, ADRB1 CCR3 331/4885TNKS 2191/4885PARP1 942/4885
US-20040242639-A1 Phospholipase C inhibitors for use in treating inflammatory disorders PLA2G4C, PLA2G4B, PLA2G5 CCR3 911/4885TNKS 1548/4885PARP1 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.